Lanreotide treatment in a patient with interferon-associated Graves' ophthalmopathy.
Su
Deng-Huang
DH
Far Eastern Polyclinic, Taipei, Taiwan.
Chang
Ying-Chun
YC
Liao
Shu-Lang
SL
Chang
Tien-Chun
TC
D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006111:Graves Disease / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D019698:Hepatitis C, Chronic / Q000188:drug therapy; D006801:Humans; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use; D008875:Middle Aged; D010456:Peptides, Cyclic / Q000627:therapeutic use*; D012254:Ribavirin / Q000627:therapeutic use; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
D000998:Antiviral Agents; D016898:Interferon-alpha; D010456:Peptides, Cyclic; C060347:lanreotide; D012254:Ribavirin; D013004:Somatostatin